(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "COVID-19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets's offering.
COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.
Extensive coverage of the COVID-19 Nucleic Acid Amplification Tests (NAATs) under development is provided in the report. It includes a thorough review of major pipeline products, encompassing product descriptions, licensing and collaboration details, and other developmental activities related to COVID-19 NAATs. The report also offers insights into the major players actively involved in the development of these tests, presenting a comprehensive list of their pipeline projects.
The coverage of pipeline products spans various stages of development, ranging from the early development phase to the approved or issued stage, providing a holistic view of the progress of COVID-19 NAATs in the development pipeline. Additionally, the report furnishes key clinical trial data specific to pipeline products, allowing for a deeper understanding of ongoing trials in this segment.
Recent developments in the COVID-19 NAATs segment and the broader industry are also covered, offering valuable insights into the latest trends and advancements in nucleic acid amplification testing for COVID-19.
Reasons to Buy
Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview
3 Products under Development
3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies
4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview
5.1 Age Labs AS Company Overview
5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments
6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus
7 Appendix
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
MENAFN16012024004107003653ID1107728400
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.